LGD-4033 vs Winstrol
Moderate Research vs Well Studied
avoid Mechanism-based · 64% Both LGD-4033 and Winstrol carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
LGD-4033 Winstrol
Weight 338.25 Da 328.49 Da
Half-life ~24-36 hours ~9 hours (oral), ~24 hours (injectable)
Type Nonsteroidal selective androgen receptor modulator (C14H12F6N2O) 17-alpha-alkylated anabolic-androgenic steroid (C21H32N2O)
Key Benefits
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
Winstrol
01 Produces a dry, hard, and vascular appearance without water retention
02 Significant strength increases without proportional weight gain, favored in weight-class sports
03 Does not aromatize to estrogen, eliminating gynecomastia and bloating concerns
04 Potent suppression of SHBG, increasing free testosterone and enhancing the effectiveness of stacked compounds
05 Available in both oral and injectable formulations
06 High anabolic-to-androgenic ratio (320:30) relative to methyltestosterone
07 FDA-approved for hereditary angioedema prophylaxis
08 Enhances vascularity and muscle definition during caloric deficit
Dosing Protocols
LGD-4033
5-10 mg/day / Once daily (oral)
Winstrol
25-50 mg/day (oral), 50 mg EOD (injectable) / Daily (oral) or every other day (injectable)
Performance - Standard Injectable 50 mg every other day Every other day (EOD)
Side Effects
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
Winstrol
Severe HDL cholesterol suppression (winstrol is among the worst oral steroids for lipid damage)
Significant LDL cholesterol elevation
Joint dryness and pain, particularly in knees, shoulders, and elbows (notorious side effect)
Hepatic stress with elevated liver enzymes (ALT/AST)
Suppression of endogenous testosterone production
Hair loss and accelerated male pattern baldness (DHT derivative, particularly harsh on hairline)
Acne and oily skin
Tendon and ligament stress due to rapid strength gains combined with reduced joint lubrication
Dry, painful shin splints during cardiovascular exercise
Contraindications
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
Known or suspected prostate cancer
Breast cancer in males
Breast cancer with hypercalcemia in females
Pregnancy (Category X - known to cause fetal harm)
Severe hepatic dysfunction or active liver disease
Nephrosis or nephrotic phase of nephritis
Pre-existing severe cardiovascular disease or dyslipidemia
Hypersensitivity to stanozolol or any formulation component
Research Evidence
LGD-4033 Winstrol
Status Moderate Research Well Studied
References 5 studies 5 studies
Latest 2018 June 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.